Research programme: Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania

Drug Profile

Research programme: Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania

Alternative Names: Pre-membrane and envelope glycoprotein mRNA-LNP; prM-E glycoprotein mRNA-LNP; Zika virus mRNA-LNP; Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania; ZIKV mRNA-LNP

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acuitas Therapeutics
  • Developer Acuitas Therapeutics; University of Pennsylvania
  • Class RNA vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 16 Mar 2018 Arbutus has issued and pending patents for LNP delivery technology in countries worldwide
  • 22 Feb 2018 Arbutus terminates Acuitas right to use or sublicense LNP technology
  • 13 Feb 2017 Preclinical data in Zika virus infection presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top